Variable | Progression-free survival | Metastasis-free survival | Overall survival | ||||
---|---|---|---|---|---|---|---|
Hazard ratio (95Â % CI) | P value | Hazard ratio (95Â % CI) | P value | Hazard ratio (95Â % CI) | P value | ||
TNFα -308G > A | GG genotype | 1 |  | 1 |  | 1 |  |
GA genotype | 4.631* | 0.005 | 4.708* | 0.010 | 4.829* | 0.037 | |
 |  | (1.587-13.512) |  | (1.445-15.345) |  | (1.098-21.243) |  |
Age group | 41-50 years | 1 | Â | 1 | Â | 1 | Â |
30-40 years | 1.451 | 0.403 | 1.407 | 0.481 | 1.014 | 0.983 | |
 |  | (0.606-3.477) |  | (0.544-3.639) |  | (0.283-3.634) |  |
Tumor size (pathologic) | T1 | 1 | Â | 1 | Â | 1 | Â |
T2 | 1.039 | 0.934 | 0.749 | 0.555 | 0.577 | 0.425 | |
 |  | (0.419-2.581) |  | (0.286-1.960) |  | (0.149-2.233) |  |
Lymph node involvement (pathologic) | N0 | 1 | Â | 1 | Â | 1 | Â |
N1 | 1.876 | 0.192 | 2.349 | 0.199 | 1.346 | 0.628 | |
 |  | (0.729-4.828) |  | (0.829-6.659) |  | (0.405-4.480) |  |
Grade | G1 | 1 | 0.962 | 1 | 0.751 | 1 | 0.629 |
G2 | 1.268 | 0.825 | 1.080 | 0.944 | 0.542 | 0.598 | |
 | (0.154-10.449) |  | (0.127-9.184) |  | (0.056-5.268) |  | |
G3 | 1.378 | 0.783 | 0.972 | 0.981 | 0.293 | 0.375 | |
 | (0.141-13.477) |  | (0.095-9.965) |  | (0.019-4.412) |  | |
Intrinsic subtype | Luminal B | 1 | 0.191 | 1 | 0.140 | 1 | 0.119 |
Luminal A | 4.095 | 0.178 | 3.329 | 0.225 | 1.380 | 0.780 | |
 | (0.526-31.892) |  | (0.419-26.433) |  | (0.144-13.257) |  | |
‘Basal-like’ | 3.872 | 0.233 | 3.248 | 0.317 | 3.966 | 0.285 | |
 | (0.420-35.739) |  | (0.324-32.593) |  | (0.318-49.534) |  | |
HER2 overexpression | 9.874* | 0.044 | 10.177* | 0.043 | 6.426 | 0.112 | |
 | (1.068-91.312) |  | (1.080-95.880) |  | (0.646-63.903) |  |